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Tonelli et al disagree with our interpretation of the
hospitalization data. While hematocrit and quality of
life were the central focus of our work, we also believe
that the hospitalization rate data suggest a benefit with
epoetin alfa. We look forward to further research to cor-
roborate these findings.
Overall, we would not represent the results in our work
as anything but what they are, a synthesis of the available
evidence with all its strengths and weaknesses. We believe
the criticisms put forth by Tonelli et al stem largely from
a misunderstanding of our article.
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Mycophenolate mofetil in IgA
nephropathy
To the Editor: We wish to raise several issues regard-
ing the publication by Maes et al [1], reporting on the
effectiveness of mycophenolate mofetil (MMF) in IgA
nephropathy (IgAN): (1) A sample of 34 patients is too
little. We have started a randomized trial, ramipril versus
ramipril plus MMF in IgAN [2]: 57 patients per group are
required to maintain a power of 80% and a type error of
5%. For a dropout rate of 10%, a total sample size of
126 patients needs to be enrolled. In the placebo group,
2 patients (1 death, 1 adverse event) out of 13 patients
(15%), and in the MMF group, 8 patients [2 end-stage
renal disease (ESRD), 2 emigrated, 1 adverse event, 1
tuberculosis (TB), 2 gastrointestinal (GI) problems] out
of 21 patients (38%) reduced or stopped the treatment
before the end of the trial.
(2) Inclusion criteria. “Eligible patients were random-
ized (2:1; MMF:placebo).” In a randomized trial all pa-
tients should have the same probability of receiving one
or the other of the treatments being compared [3]. Renal
function for inclusion was taken at the time of diagnosis
(ie, 0 to 5 years back from randomization). Were patients
with glomerular filtration rate (GFR) <20 mL/min in-
cluded? Options for eligibility were also hypertension,
proteinuria, and histologic severity, alone or in combina-
tion. Were these risk factors evenly distributed between
groups?
(3) A wash-out period for patients assuming enalapril
was not performed, biasing proteinuria at entry.
(4) In a small patient sample, data distribution is not
usually normal and a nonparametric approach would
have been more appropriate.
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We agree that, from a statistical point of view, the study
is not powered to prove differences or equivalence be-
tween the two groups. Therefore, large multicenter trials
are warranted. Even a study of 126 patients is small to un-
equivocally prove superiority of mycophenolate mofetil
(MMF) treatment over standard renoprotective treat-
ment (including salt restriction, angiotensin II suppres-
sion) plus frequent follow-up (compliance). Using the
data from our study population, the number of patients
per group after dropout would have to be 83 to maintain
a power of 80% and an a-value of 0.05 [1, 2]. Because that
number could not be reached, a 2:1 randomization was
performed in order to maximize the number of patients
exposed to MMF. We clearly stated this in the abstract
and discussion section of the manuscript.
As stated, patients with GFR <20 mL/min were ex-
cluded, and risk factors did not differ significantly be-
tween groups alone or in combination.
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There was indeed no washout period of enalapril; how-
ever, only 27% of patients were on enalapril at entry [29%
in the MMF group and 23% in the placebo group; P =
0.7867 (chi-square)]. The lack of impact of MMF on renal
function noted in our study is difficult to explain by this
phenomenon.
Because of small sample size, the data were ana-
lyzed using nonparametric statistics (Wilcoxon rank sum
test, chi-square test, linear mixed models), applicable to
both normal and non-normal distributed sample data
[2, 3].
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Hepatic iron in hemodialysis
patients
To the Editors: Canavese et al [1] reported that hepatic
iron overload is common in hemodialysis patients, and
suggested a reevaluation of acceptable iron parameters.
This was a well-designed study, and the work is an impor-
tant contribution to our knowledge on iron storage in this
patient population. It should be noted, however, that it
may not be reasonable to extrapolate these results to the
general hemodialysis population. To properly answer the
question of how prevalent iron overload is in hemodial-
ysis patients, an unselected group of patients should be
studied. This was not true of Canavese’s cohort. Thirty
out of 40 subjects (75%) had to discontinue 15 months
of continuous intravenous iron therapy due to serum fer-
ritin >500 ng/mL. Therefore, there was a strong selection
bias towards an iron-overloaded subpopulation.
It should be noted that the major finding of this study,
that many patients on hemodialysis had mild to moderate
hepatic iron “overload,” is not a new finding. More than
20 years ago, Ali et al [2] and Gokal et al [3] performed au-
topsy studies and found excess hepatic iron in hemodialy-
sis patients. In contrast to Canavese’s study, these authors
had access to hepatic tissue, allowing them to determine if
the excess iron was found in association with tissue dam-
age. Ali found significant iron excess in the livers of 48%
of subjects. Importantly, no liver pathology or damage
was found, even in cases of severe iron overload. Indeed,
anecdotally, there does not appear to be any excess preva-
lence of cirrhosis among hemodialysis patients. The fact
that hepatic tissue damage does not seem to coexist with
hepatic iron overload suggests that hepatic iron excess,
as found by Ali, Gokal, and Canavese, may simply be a
reflection of shifted iron pools. Indeed, an elevated serum
ferritin (iron storage marker) concurrent with low or nor-
mal transferrin saturation (iron circulation marker) is a
frequent finding in hemodialysis patients, consistent with
a shift of iron pools away from the circulation and into
storage tissues. Inflammation may be the key central link
and driver of this process. Recently, a strong association
was found between measures of inflammation and serum
ferritin [4, 5]. The phenomenon may best be understood
as inflammation leading to a state of reticuloendothelial
blockade that causes hemodialysis patients to have in-
creased hepatic storage of poorly mobile iron.
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The impact of serum uric acid
on cardiovascular outcomes in
the LIFE study
To the Editor: The analysis of the role of serum uric
acid (SUA) levels in the Losartan In tervention for End-
point reduction in hypertension study (LIFE) study is of
